AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Eyespy 20204/12/2023 The company, which is based in Europe, is growing very quickly and works in multiple industries. Ideal for: Listing agents, teams and brokerages wanting to embrace virtual tour marketing Top selling points: EyeSp圓60 is a 360-degree imaging and virtual tour provider. prepared the first draft.Have suggestions for products that you’d like to see reviewed by our real estate technology expert? Email Craig Rowe. contributed to funding acquisition and L.E., C.C. BoergerĪll authors were involved in the conceptualization and writing and/or editing of this correspondence. Yale School of Medicine, New Haven, CT, USA Yen, Gregory Peterfreund, Brett Lindgren, Jerry S. University of Southern California, Los Angeles, CA, USAĪlbert F. Keck School of Medicine, USC, Los Angeles, CA, USA Kaiser Permanente Southern California Physicians Group, Los Angeles, CA, USA University of Pennsylvania, Philadelphia, PA, USA University of Colorado, School of Medicine, Aurora, CO, USA University of California Irvine, Orange, CA, USA Albertson, Angela Haczku, Erin Hardy, Brian M. University of California Davis, Sacramento, CA, USA Northwestern University Feinberg School of Medicine, Chicago, IL, USA Montefiore Medical Center, New York, NY, USAĪlbert Einstein College of Medicine, New York, NY, USAīrenda Lopez, Omowunmi Amosu & Hiwet Tzehaie Angelucci, Fredy Chaparro-Rojas, Mitchell P. Lankenau Institute for Medical Research, Wynnewood, PA, USAĮliot B. Reyes, Michelle Jung, Marylee Melendrez, Lissette Rosario-Remigio & Henry Su Youssef, Maged Tanios, Daniel Blevins, Laura R. Long Beach Medical Center, Long Beach, CA, USAįady A. Obermiller, Bethany Weiler-Lisowski, Lucia Kufa, Paul L. Logan Health Research Institute, Kalispell, MT, USA Robinson, Farjad Sarafian, Esmeralda Martinez, Patrice Jones & Julie Nguyen Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA Medstar Georgetown University Hospital, Washington, DC, USA Harris, Christina Creel-Bulos, Philip Yang, Joshua F. Dzierba, Justin Muir & Katarzyna GosekĬolumbia University College of Physicians and Surgeons, New York, NY, USA New York Presbyterian Hospital, New York, NY, USAĪmy L. University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA University of Alabama at Birmingham, Birmingham, AL, USA Thomas, Mary LaRose, Leigha Landreth, Lisa Parks & Harsh V. Wake Forest Baptist Health, Winston-Salem, NC, USAĭaniel C. Lupu & Michelle MeyersĪlessio Crippa, Andrea Discacciati & Martin Eklund Berger III, Chirag Patel, Austin Simonson, Jamal Dodin, Tony Oliver, Roxana A. Sanford Medical Center, Sioux Falls, SD, USA Serra, Amanda Rosen, Ivan Garcia, John Schicchi, Anita Darmanian & Romina Wahab Asare, Paul Henderson & Ruixiao LuĬolumbia University Irving Medical Center, New York, NY, USA QuantumLeap Healthcare Collaborative, San Francisco, CA, USAĪdam L. Esserman, Alejandra Jauregui, Scott Fields, Diana Ng, Brian M. University of California San Francisco, San Francisco, CA, USAĬarolyn S. These authors contributed equally: Carolyn S. Similar approaches may be useful in future pandemic settings when disease mechanisms are poorly defined, multiple agents need to be rapidly triaged, and/or there is potential for major therapeutic wins. These design decisions have enabled fast progress, with the caveat that I-SPY COVID is signal-finding rather than definitive and so subsequent phase 3 studies will be required for agents that graduate from the trial. Moreover, we determined at the outset to seek strong signals of efficacy, while accepting the risk of missing more modest benefits in exchange for the goal of rapidly cycling and testing several agents at a time. Features such as the open-label design and the comparative effectiveness approach that forgoes placebo permit flexibility, particularly with variable routes of administration (intravenous, subcutaneous, inhaled). What are the lessons learned from this trial experience that may have important implications for future pandemics and/or clinical trials in a similar treatment space? First, there is a unique niche for phase 2 clinical trials that can rapidly evaluate repurposed or novel agents for which preliminary safety data exist, but fewer data are available in support of efficacy than would be advisable in a standard phase 3 study.
0 Comments
Read More
Leave a Reply. |